TWP
BCRX icon

TFO Wealth Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

TFO Wealth Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$15 – 135
2024
Q1 		$15 Hold
3
– – ﹤0.01% 777
2023
Q4 		$18 Hold
3
– – ﹤0.01% 920
2023
Q3 		$21 Hold
3
– – ﹤0.01% 1088
2023
Q2 		$21 Hold
3
– – ﹤0.01% 811
2023
Q1 		$25 Buy
3
+1
+50% +$10 ﹤0.01% 786
2022
Q4 		$160 Buy
+2
New +$25 ﹤0.01% 672

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TFO Wealth Partners's BCRX Position: Q2 2024 in Review

TFO Wealth Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 3 shares — an estimated $15 sold.

TFO Wealth Partners first reported a position in BCRX in Q4 2022 and held it in 6 quarters. The position peaked at $160 in Q4 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • TFO Wealth Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • TFO Wealth Partners sold 3 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $15.
  • TFO Wealth Partners first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • TFO Wealth Partners's BioCryst Pharmaceuticals position peaked at $160 in Q4 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on TFO Wealth Partners's 13F filing for Q2 2024, filed 15 Aug 2024.